AU Patent

AU2023208070B2 — Cancer diagnostic imaging agents

Assigned to Technische Universitaet Muenchen · Expires 2025-09-04 · 1y expired

What this patent protects

#$%^&*AU2023208070B220250904.pdf##### Abstract The present invention relates to a ligand-SIFA-chelator conjugate, comprising, within a single molecule three separate moieties: (a) one or more ligands which are capable of binding to PSMA, (b) a silicon-fluoride acceptor (SI…

USPTO Abstract

#$%^&*AU2023208070B220250904.pdf##### Abstract The present invention relates to a ligand-SIFA-chelator conjugate, comprising, within a single molecule three separate moieties: (a) one or more ligands which are capable of binding to PSMA, (b) a silicon-fluoride acceptor (SIFA) moiety which comprises a covalent bond between a silicon atom and a fluorine atom, and (c) one or more chelating groups, containing a chelated nonradioactive cation. Abstract The present invention relates to a ligand-SIFA-chelator conjugate, comprising, within a single 2023208070 24 Jul 2023 molecule three separate moieties: (a) one or more ligands which are capable of binding to PSMA, (b) a silicon-fluoride acceptor (SIFA) moiety which comprises a covalent bond between a silicon atom and a fluorine atom, and (c) one or more chelating groups, containing a chelated nonradioactive cation.

Drugs covered by this patent

Patent Metadata

Patent number
AU2023208070B2
Jurisdiction
AU
Classification
—
Expires
2025-09-04
Drug substance claim
No
Drug product claim
No
Assignee
Technische Universitaet Muenchen
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.